Hepatitis B Virus Core Antigen (HBcAg) antibody (Biotin)
-
- Target See all Hepatitis B Virus Core Antigen (HBcAg) Antibodies
- Hepatitis B Virus Core Antigen (HBcAg)
-
Reactivity
- Hepatitis B Virus (HBV), Virus
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- Biotin
-
Application
- ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
- Cross-Reactivity
- Virus
- Cross-Reactivity (Details)
- Hepatitis B Virus
- Purification
- Purified by Protein G.
- Immunogen
- Recombinant Hepatitis B Core Antigen (rHBcAg)
- Clone
- 1H8
- Isotype
- IgG
- Top Product
- Discover our top product HBcAg Primary Antibody
-
-
- Application Notes
- IHC-P 1:200-400
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1 μg/μL
- Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
- Preservative
- ProClin
- Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- Storage
- -20 °C
- Storage Comment
- Store at -20°C for 12 months.
- Expiry Date
- 12 months
-
- Target
- Hepatitis B Virus Core Antigen (HBcAg)
- Alternative Name
- HBcAg (HBcAg Products)
- Synonyms
- precore; HBe antigen; PreC; HBeAg; precore protein; external core antigen; HBeAg; p25 antibody, C antibody
- Target Type
- Viral Protein
- Background
-
Synonyms: C, Capsid protein, Core and e antigen, Core antigen, Core antigen, Core protein, HBc, HBcAg, HBVgp4, Hepatitis B Virus core antigen, p21.5, precore/core protein, CAPSD_HBVA3.
Background: Hepatitis B Virus Core Antigen (HBcAg) is part of the infectious virion containing an inner "core particle" enclosing the viral genome. The icosahedral core particle contains 180 or 240 copies of the core protein. HBcAg is one of the three major clinical antigens of hepatitis B virus but disappears early in the course of infection.The hepatitis B virus core antigen (HBcAg) is a highly immunogenic subviral particle and functions as both a T-cell-dependent and a T-cell-independent antigen. Therefore, HBcAg may be a promising candidate target for therapeutic vaccine control of chronic HBV infection.
-